# Ordaos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ordaos

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.ordaos.bio
- Total disclosed funding: $5M
- Latest round: Seed (Aug 25, 2022)
- Investors on record: 5

## About

Based in New York, US, and founded in 2019, Ordaos, Inc. is the provider of life-saving treatment through its creation mini – protein. In August 2022, the firm raised USD 5 million in Seed funding led by investor VTC Ventures, with participation from other investors Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. As of 2022 company is headed by its CEO David Longo.

The company offers flagship solution miniPRO™ proteins that help in delivering safe and effective treatments. miniPRO™ proteins provide the power and performance of antibodies but can be easily scale-up, configured, and manufactured. Additionally, the firm also provides birth novel therapies that reduce the patient’s suffering, improve their health, and extend their life.

The company plans to use the August 2022 funding for product development and expand partner acquisition efforts, as well as to accelerate drug design and discovery.

## Funding rounds

- Seed, Aug 25, 2022, $5M — Route 66 Ventures, IAG Capital Partners, VTC Ventures, Citta Capital, Banyan Pacific Capital

## Investors

- Route 66 Ventures (https://capitalatlas.ai/funds/route-66-ventures) — Seed
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Seed
- VTC Ventures (https://capitalatlas.ai/funds/vtc-ventures) — Seed
- Citta Capital — Seed
- Banyan Pacific Capital — Seed